OncologyTube Professional - Patients Click Here

154,375 video views
Loading........
Description: Robert Z. Orlowski, MD, PhD, from The University of Texas MD Anderson Cancer Center discusses combinations well tolerated in multiple Myeloma and that benefits are better when compared to lenalidomide...
01:00
Sudipto Mukherjee, MD from Cleveland Clinics discusses promising novel agents that can change the treatment landscape and FLT3 and IDH1 inhibitors, luspatercept at the 2017 American Society of Hematology.
by:ASHReport | 171 views
01:06
Jonathan Gerber, MD from Levine Cancer Institute discusses hopeful for the FDA approval of the IDH1 inhibitor and new generation of inhibitors like FLT3 are hopefully more effective at the 2017 American Society of Hematology.
by:ASHReport | 207 views
02:09
Aaron Gerds, MD from Cleveland Clinics discusses new forms of interferon have improved side-effect profiles and pegylated interferon and ropeginterferon lasts much longer at the 2017 American Society of Hematology.
by:ASHReport | 281 views
01:38
Sudipto Mukherjee, MD from Cleveland Clinics discusses personalized prediction model for Myelodysplastic Syndromes and certain mutations predict non-malignant conditions at the 2017 American Society of Hematology.
by:ASHReport | 212 views
00:58
Jonathan Gerber, MD from Levine Cancer Institute discusses new agents becoming available for the 1st time in decades and what agents can be safely combined in pre & post transplant therapy at the 2017 American Society of Hematology.
by:ASHReport | 181 views
01:01
Sudipto Mukherjee, MD from Cleveland Clinics discusses two areas that potentially cut down rehospitalizati​ons and follow patients to be on top of their health and manage symptoms at the 2017 American Society of Hematology.
by:ASHReport | 112 views
01:23
Aaron Gerds, MD from Cleveland Clinics discusses patients showed symptomatic relief in Phase I Trial of Glasdegib and 35% of patients had at least a 20% improvement in their symptom burden at the 2017 American Society of Hematology.
by:ASHReport | 65 views
01:02
Jonathan Gerber, MD from Levine Cancer Institute discusses 9 out of 10 achieved remission with Hypomethylating agent and next phase is to expand as a viable approach for elderly patients at the 2017 American Society of Hematology.
by:ASHReport | 69 views
01:11
Sudipto Mukherjee, MD from Cleveland Clinics discusses preliminary findings of unplanned hospital readmissions and conclusive data may identify patients to cut down readmission rates at the 2017 American Society of Hematology.
by:ASHReport | 57 views
01:23
Aaron Gerds, MD from Cleveland Clinics discusses Phase 2 Trial of Glasdegib in myelofibrosis was not launched - due to modest overall response in clinical activity at the 2017 American Society of Hematology.
by:ASHReport | 136 views

About ASHReport


Links
Channel Url: